LONDON: Researchers have found that a type of asthma drug may halve a patient's

risk of developing Parkinson's disease, a chronic disease with unknown causes. The
disease destroys the brain cells that control body movements. Shivering, stiff arms
and legs and poor coordination are typical symptoms of Parkinson's. The symptoms
may develop slowly, and it sometimes takes time to make a correct diagnosis. The
findings, published in the journal Science, could lead to new treatment of
Parkinson's patients. "Our discoveries may be the start of a totally new possible
treatment for this serious disease. We expect that clinical studies will follow
these discoveries," said Trond Riise, Professor at Department of Global Public
Health and Primary Care (IGS), University of Bergen in Norway. Examining the
pharmaceutical history of more than four million Norwegians over an 11-year period,
the researchers found that Beta2-adrenoreceptor agonists may reduce Parkinson's
disease. The medicine regulates expression of levels of SNCA gene linked to
Parkinson's disease risk, the study said. For the study, the researchers examined
more than 100 million Norwegian prescriptions registered since 2004. "Our analysis
of data from the whole Norwegian population has been decisive for the conclusion in
this study," Riise said. ?? ???? ??? ?? ??? ????? ??? ???? ????, ??????
1 ???? ??????Refollium????? ????? ???? ???, 12 ????? ?? Free ?????? ?? ???!
Truebil.comRecommended By Colombia In the study, the treatment of Parkinson's was
linked to prescriptions of asthma medicine and the medicine for high blood
pressure. The Norwegian analysis was done after researchers at Harvard University
found these effects of the medicines in animal tests and in experiments with brain
cells in the lab. Latest CommentIf it really works, then it would be a boon to the
potential Parkinson''s patients.dasdeebee To find out if these medicines had the
same effect on humans, the researchers at Harvard University started to collaborate
with the Norwegian research team. "We analysed the whole Norwegian population and
found the same results as in the animal testing at Harvard University. These
medicines have never been studied in relation to Parkinson's disease," Riise said.